Mirum Pharmaceuticals (NASDAQ:MIRM) reported first-quarter 2026 results and outlined plans to expand both its commercial ...

Brelovitug Phase 2b portion of AZURE-1 study met primary endpoint - In-licensed exclusive worldwide rights to zilurgisertib ...

Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing ...

Entering what Mirum Pharmaceuticals Inc. CEO Chris Peetz called “a new phase of growth and value creation,” the company plans to submit an NDA to the U.S. FDA in the second half of this year, based on ...

Chief Executive Officer — Christopher Peetz President and Chief Operating Officer — Peter Radovich Chief Medical Officer — Joanne M. Quan Chief Financial Officer — Eric Bjerkholt Christopher Peetz: ...

Management expects completion of VISTAS study enrollment for Volixibat in PSC in the third quarter of 2025, with data readout expected in the second quarter of 2026. Recently approved CTEXLI is ...

Image source: The Motley Fool. Mirum Pharmaceuticals (NASDAQ:MIRM) reported record quarterly revenue growth and raised its full-year guidance, citing solid commercial execution and new regulatory ...

Andrew McKibben: Thank you, Elliot, and good afternoon, everyone. I would like to welcome you to Mirum Pharmaceuticals, Inc.'s fourth quarter and full year 2025 Conference Call. I am joined today by ...

- 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected Q2 2026 - LIVMARLI® EXPAND study in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Foster City's Mirum ...